

Molecular, biochemical, and cellular pharmacology of p

Seminars in Oncology

29, 3-17

DOI: [10.1053/sonc.2002.37461](https://doi.org/10.1053/sonc.2002.37461)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment of Ovarian Hyperstimulation Syndrome. , 2001, , 200-226.		0
4	The epidermal growth factor receptor as a novel target for cancer therapy: Case studies and clinical implications. Seminars in Oncology Nursing, 2002, 18, 11-19.	0.7	10
5	The role of new agents in the treatment of non-small cell lung cancer. European Journal of Cancer, 2002, 38, 2347-2361.	1.3	33
6	Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. Seminars in Oncology, 2002, 29, 2-8.	0.8	9
7	What's new in urology. Journal of the American College of Surgeons, 2002, 195, 663-674.	0.2	4
8	RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene, 2002, 21, 6908-6914.	2.6	146
9	Biologic directed therapies in gynecologic oncology. Current Oncology Reports, 2003, 5, 459-467.	1.8	3
10	Novel antifolate drugs. Current Oncology Reports, 2003, 5, 114-125.	1.8	90
11	Neue Substanzen und neue Wirkprinzipien in der Onkologie. Onkologe, 2003, 9, 1058-1087.	0.7	0
12	Molecularly Targeted Chemoprevention of Lung Cancer. Clinical Lung Cancer, 2003, 4, 269-272.	1.1	0
13	The Role of Pemetrexed (Alimta®, LY231514) in Lung Cancer Therapy. Clinical Lung Cancer, 2003, 5, 21-27.	1.1	19
14	Pemetrexed (alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma. Seminars in Oncology, 2003, 30, 32-36.	0.8	20
15	Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-? in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer, 2003, 98, 758-764.	2.0	104
16	Effect of methylenetetrahydrofolate reductase 677C>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. International Journal of Cancer, 2003, 103, 294-299.	2.3	122
17	Quality of life in myelofibrosis with myeloid metaplasia: a cross-sectional study. Leukemia Research, 2003, 27, 763-764.	0.4	2
18	The epidermal growth factor receptor mediates radioresistance. International Journal of Radiation Oncology Biology Physics, 2003, 57, 246-254.	0.4	272
19	Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Critical Reviews in Oncology/Hematology, 2003, 46, 67-83.	2.0	44
20	Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Critical Reviews in Oncology/Hematology, 2003, 46, 105-115.	2.0	40

#	ARTICLE	IF	CITATIONS
21	The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 163-168.	1.2	29
22	Tumor hypoxia: A target for selective cancer therapy. <i>Cancer Science</i> , 2003, 94, 1021-1028.	1.7	329
23	Biologic and therapeutic role of HER2 in cancer. <i>Oncogene</i> , 2003, 22, 6570-6578.	2.6	379
24	Resistance to antifolates. <i>Oncogene</i> , 2003, 22, 7431-7457.	2.6	249
25	Monoclonal antibody therapeutics and apoptosis. <i>Oncogene</i> , 2003, 22, 9097-9106.	2.6	69
26	Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor. <i>Oncogene</i> , 2003, 22, 8509-8518.	2.6	51
27	Imaging of angiogenesis: from microscope to clinic. <i>Nature Medicine</i> , 2003, 9, 713-725.	15.2	943
28	Ovarian cancer: strategies for overcoming resistance to chemotherapy. <i>Nature Reviews Cancer</i> , 2003, 3, 502-516.	12.8	1,005
29	Translating angiogenesis research into the clinic: the challenges ahead. <i>British Journal of Radiology</i> , 2003, 76, S3-S10.	1.0	36
30	Vascular endothelial growth factorâ€™ mediator of OHSS?. <i>Fertility and Sterility</i> , 2003, 79, 1466-1467.	0.5	3
31	Primary and Secondary Prevention of Nonâ€™ Small-Cell Lung Cancer: The SPORE Trials of Lung Cancer Prevention. <i>Clinical Lung Cancer</i> , 2003, 5, S36-S40.	1.1	12
32	Chronic obstructive pulmonary disease: molecular and cellular mechanisms. <i>European Respiratory Journal</i> , 2003, 22, 672-688.	3.1	1,174
33	Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways. <i>American Journal of Pathology</i> , 2003, 163, 1949-1960.	1.9	203
34	ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. <i>Lung Cancer</i> , 2003, 40, 301-307.	0.9	31
35	Gefitinib (Iressa) trials in non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 41, 23-28.	0.9	42
36	Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. <i>Lung Cancer</i> , 2003, 41, 29-42.	0.9	189
37	Advanced NSCLC: new cytostatic agents. <i>Lung Cancer</i> , 2003, 41, 123-132.	0.9	8
38	Lung cancer chemoprevention: moving from concept to a reality. <i>Lung Cancer</i> , 2003, 41, 163-174.	0.9	13

#	ARTICLE	IF	CITATIONS
39	Chemoprevention of lung cancer: current status and future prospects. <i>Lung Cancer</i> , 2003, 42, 71-79.	0.9	19
40	Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells. <i>Urology</i> , 2003, 61, 468-473.	0.5	15
41	Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification. <i>Annals of Thoracic Surgery</i> , 2003, 76, 1319-1326.	0.7	6
42	Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2003, 15, 438-447.	0.4	3
43	Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2003, 4, 397-406.	5.1	268
45	Promising New Approaches in the Treatment of Advanced Head and Neck Cancer. <i>American Journal of Cancer</i> , 2003, 2, 335-347.	0.4	1
46	PATHOGENESIS OF RESPIRATORY DISEASES: NEW SOLUTIONS TO OLD PROBLEMS?. <i>Experimental Lung Research</i> , 2003, 29, 3-92.	0.5	0
47	Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15871-15876.	3.3	94
48	Current treatments and future perspectives in colorectal and gastric cancer. <i>Annals of Oncology</i> , 2003, 14, ii49-ii55.	0.6	40
50	The Medical Management of Pancreatic Cancer: A Review. <i>Oncologist</i> , 2003, 8, 149-160.	1.9	43
51	Epidermal Growth Factor Receptor in Non-“Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. <i>Journal of Clinical Oncology</i> , 2003, 21, 3798-3807.	0.8	1,333
52	Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1174-1175.	3.0	5
53	RESPONSE: Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1175-1175.	3.0	0
54	Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 4356-4363.	0.8	78
55	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancer Nursing</i> , 2003, 26, 21S-25S.	0.7	10
56	Bile acids activate EGF receptor via a TGF- $\beta$ -dependent mechanism in human cholangiocyte cell lines. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, G31-G36.	1.6	134
57	Anti-angiogenic Effects of Dimethyl Sulfoxide on Endothelial Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2003, 26, 1295-1298.	0.6	25
58	Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience from a Single Institution. <i>Cancer Control</i> , 2003, 10, 388-395.	0.7	35

#	ARTICLE	IF	CITATIONS
59	Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, S16-S21.	0.5	1
60	Polycythemia Vera: A Review. <i>Clinical Journal of Oncology Nursing</i> , 2003, 7, 553-556.	0.3	6
62	Pharmacy practice issues with targeted therapy for lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, S11-S15.	0.5	7
63	Angiogenesis Inhibitors: Current & Future Directions. <i>Current Pharmaceutical Design</i> , 2004, 10, 1-9.	0.9	26
64	Colorectal Polyposis and Immune-Based Therapies. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2004, 18, 239-249.	1.8	8
65	Inhibition of Epidermal Growth Factor Receptor and Symptom Improvement in Advanced Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2004, 25, 29-32.	0.8	0
67	Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts. <i>Cancer Research</i> , 2004, 64, 4601-4610.	0.4	52
68	The Role of $\hat{\pm}$ -Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs. <i>Clinical Cancer Research</i> , 2004, 10, 1080-1089.	3.2	69
69	Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 136-143.	3.2	143
70	Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. <i>Annals of Oncology</i> , 2004, 15, 786-792.	0.6	51
71	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 8613-8619.	3.2	17
72	Handbook of Cancer Vaccines. , 2004, , .		5
73	Treatment of Carcinogenesis. , 2004, , 607-673.		1
74	Malignant Pleural Mesothelioma. <i>Chest</i> , 2004, 126, 1318-1329.	0.4	125
75	Overexpression of Cyclin D1 Is Associated with Poor Survival in Epithelial Ovarian Cancer. <i>Oncology</i> , 2004, 66, 310-315.	0.9	53
76	Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines. <i>International Journal of Molecular Medicine</i> , 2004, 13, 865.	1.8	8
77	EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. <i>Cancer Biology and Therapy</i> , 2004, 3, 1243-1249.	1.5	57
78	PPAR $\gamma$ Signaling: One Size Fits All?. <i>Cell Cycle</i> , 2004, 3, 1352-1354.	1.3	5

#	ARTICLE	IF	CITATIONS
79	Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues. Journal of Histochemistry and Cytochemistry, 2004, 52, 893-901.	1.3	317
80	Restoration of Transport Activity by Co-expression of Human Reduced Folate Carrier Half-molecules in Transport-impaired K562 Cells. Journal of Biological Chemistry, 2004, 279, 46755-46763.	1.6	14
81	New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers. Oncologist, 2004, 9, 282-294.	1.9	77
82	Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (Iressa™, ZD1839) in non-small-cell lung cancer. British Journal of Cancer, 2004, 91, 208-212.	2.9	204
83	Wnt Signaling and Breast Cancer. Cancer Biology and Therapy, 2004, 3, 36-41.	1.5	288
84	Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric. Oncology, 2004, 67, 27-32.	0.9	55
85	Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor. Journal of Clinical Oncology, 2004, 22, 175-184.	0.8	257
86	Nursing Considerations for Administering Pemetrexed (Alimta®) in Combination With Cisplatin for Malignant Pleural Mesothelioma. Clinical Journal of Oncology Nursing, 2004, 8, 242-247.	0.3	1
87	HIFs and tumors—causes and consequences. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 286, R608-R623.	0.9	416
88	Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene, 2004, 23, 4624-4635.	2.6	70
89	Oncogenomics and the development of new cancer therapies. Nature, 2004, 429, 469-474.	13.7	92
90	Antiangiogenic cancer therapy. Seminars in Cancer Biology, 2004, 14, 139-145.	4.3	102
91	Signaling through the epidermal growth factor receptor during the development of malignancy. , 2004, 102, 37-46.		265
92	2004 Highlights From: 40th Annual Meeting of the American Society of Clinical Oncology New Orleans, Louisiana June 2004. Clinical Lung Cancer, 2004, 6, 11-16.	1.1	0
93	Molecular approach to breast cancer treatment. Seminars in Oncology, 2004, 31, 6-13.	0.8	66
94	Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Seminars in Oncology, 2004, 31, 25-33.	0.8	31
95	Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Seminars in Oncology, 2004, 31, 10-16.	0.8	14
96	Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecologic Oncology, 2004, 93, 209-214.	0.6	41

#	ARTICLE	IF	CITATIONS
97	Therapeutic Advances in Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 6, 154-161.	1.1	11
98	Pemetrexed Alone and in Combination with Platinum Compounds in the Management of Malignant Mesothelioma. <i>Clinical Lung Cancer</i> , 2004, 5, S56-S60.	1.1	1
99	How does the immune system attack cancer?. <i>Current Problems in Surgery</i> , 2004, 41, 15-132.	0.6	14
100	Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. <i>Cancer Detection and Prevention</i> , 2004, 28, 244-251.	2.1	71
101	Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. <i>Cellular Signalling</i> , 2004, 16, 13-19.	1.7	120
102	The epigenetics of ovarian cancer drug resistance and resensitization. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 1552-1572.	0.7	156
103	The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. <i>Angiogenesis</i> , 2004, 7, 225-233.	3.7	149
104	Apoptosis in cancer: Archaeology, functional relevance and exploitation in novel treatment strategies. <i>Irish Journal of Medical Science</i> , 2004, 173, 40-47.	0.8	1
105	Review of epidermal growth factor receptor biology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, S21-S26.	0.4	1,094
106	Radiofrequency Ablation of Cancer. <i>CardioVascular and Interventional Radiology</i> , 2004, 27, 427-34.	0.9	89
107	Improved potency of cisplatin by hydrophobic ion pairing. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 441-448.	1.1	30
108	Novel therapies for pancreatic adenocarcinoma. <i>Current Gastroenterology Reports</i> , 2004, 6, 119-125.	1.1	14
109	Novel therapies for pancreatic adenocarcinoma. <i>Current Oncology Reports</i> , 2004, 6, 199-206.	1.8	20
110	Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. <i>Journal of Pathology</i> , 2004, 204, 101-109.	2.1	128
111	Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa™) is independent of EGFR expression level. <i>Journal of Cellular Physiology</i> , 2004, 198, 259-268.	2.0	108
112	Targeting the EGFR in neoplasia—more questions than answers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 899-902.	0.4	2
113	Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 361-368.	0.4	12
114	A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1215-1227.	0.4	155

#	ARTICLE	IF	CITATIONS
115	Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, S11-S20.	0.4	27
116	Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. <i>Biomaterials</i> , 2004, 25, 2789-2798.	5.7	152
117	Chemoprevention in lung cancer. <i>Current Problems in Cancer</i> , 2004, 28, 287-306.	1.0	3
118	Chemoprevention of lung cancer—from biology to clinical reality. <i>Annals of Oncology</i> , 2004, 15, 185-196.	0.6	38
120	Angiogenesis in colorectal cancer: therapeutic implications and future directions. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 1087-1119.	0.9	5
121	Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal intergroup pancreatic cancer task force. <i>Surgical Oncology Clinics of North America</i> , 2004, 13, 751-760.	0.6	10
122	Thrombocytosis. <i>New England Journal of Medicine</i> , 2004, 350, 1211-1219.	13.9	335
123	Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. <i>Lung Cancer</i> , 2004, 45, 93-104.	0.9	182
124	Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. <i>Lung Cancer</i> , 2004, 45, 197-205.	0.9	18
125	Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. <i>Journal of Translational Medicine</i> , 2004, 2, 6.	1.8	94
126	Site-Specific Conjugation of Boron-Containing Dendrimers to Anti-EGF Receptor Monoclonal Antibody Cetuximab (IMC-C225) and Its Evaluation as a Potential Delivery Agent for Neutron Capture Therapy. <i>Bioconjugate Chemistry</i> , 2004, 15, 185-194.	1.8	176
127	Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer. <i>Cancer Research</i> , 2004, 64, 8919-8923.	0.4	1,168
128	Mediators of Chronic Obstructive Pulmonary Disease. <i>Pharmacological Reviews</i> , 2004, 56, 515-548.	7.1	604
129	Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 1143-1159.	0.9	9
130	Recent advances in management of small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 521-543.	3.4	69
131	Constitutive and inducible expression and regulation of vascular endothelial growth factor. <i>Cytokine and Growth Factor Reviews</i> , 2004, 15, 297-324.	3.2	146
132	The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma. <i>European Journal of Cancer</i> , 2004, 40, 515-520.	1.3	122
133	Predicting non-small cell lung cancer expression of epidermal growth factor receptor and matrix metalloproteinase 9 from immunohistochemical staining of diagnostic biopsy samples. <i>European Journal of Cancer</i> , 2004, 40, 1589-1592.	1.3	9



#	ARTICLE	IF	CITATIONS
134	N-Acetyl-Cysteine Promotes Angiostatin Production and Vascular Collapse in an Orthotopic Model of Breast Cancer. <i>American Journal of Pathology</i> , 2004, 164, 1683-1696.	1.9	62
135	Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor. <i>Cancer Research</i> , 2004, 64, 3586-3592.	0.4	65
136	Growth factor receptors as targets for lung cancer therapy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2004, 16, 3-12.	0.4	17
137	Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. <i>Radiotherapy and Oncology</i> , 2004, 72, 221-230.	0.3	58
138	Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy. <i>Annals of Surgery</i> , 2004, 240, 644-658.	2.1	1,145
139	Early and Late Complications After Radiofrequency Ablation of Malignant Liver Tumors in 608 Patients. <i>Annals of Surgery</i> , 2004, 239, 450-458.	2.1	336
140	Modulation of angiogenesis in patients with myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 623-639.	0.7	11
141	Biomarkers in non-small cell lung cancer prevention. <i>European Journal of Cancer Prevention</i> , 2004, 13, 425-436.	0.6	27
142	Drug Transporters and Their Role in Tissue Distribution. <i>Annual Reports in Medicinal Chemistry</i> , 2004, 39, 277-291.	0.5	1
143	Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods. <i>Biochemical Journal</i> , 2004, 378, 201-206.	1.7	25
144	Roles of USF, Ikaros and Sp proteins in the transcriptional regulation of the human reduced folate carrier B promoter. <i>Biochemical Journal</i> , 2004, 383, 249-257.	1.7	30
145	ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer. <i>Chest</i> , 2005, 127, 978-983.	0.4	264
146	Structural Determinants of Folate and Antifolate Membrane Transport by the Reduced Folate Carrier. , 2005, , 291-318.		5
147	Expression of Vascular Endothelial Growth Factor and Proliferation Marker MIB1 Are Influenced by Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. <i>Applied Immunohistochemistry &amp; Molecular Morphology</i> , 2005, 13, 147-156.	2.0	7
148	c-Src Regulates Constitutive and EGF-mediated VEGF Expression in Pancreatic Tumor Cells Through Activation of Phosphatidyl Inositol-3 Kinase and p38 MAPK. <i>Pancreas</i> , 2005, 31, 263-274.	0.5	59
149	EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 633-639.	2.1	229
150	Development of Precise Pharmacodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. <i>Acta Histochemica Et Cytochemica</i> , 2005, 38, 209-216.	0.8	1
151	Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-?? (TGFA) gene and risk of oral cancer in Puerto Rico. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 343-347.	0.7	30

#	ARTICLE	IF	CITATIONS
152	Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 908-914.	0.4	46
153	Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC). <i>Journal of Orthopaedic Research</i> , 2005, 23, 1004-1012.	1.2	26
154	Treatment Considerations for the Management of Fibrodysplasia Ossificans Progressiva. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2005, 3, 243-250.	1.3	39
155	New Drugs for Colorectal Cancer (Irinotecan, Oxaliplatin, Raltitrexed) Meet Expectations in Routine Practice: A Single Center's Experience Before and After Their Introduction. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 35, 069-076.	0.4	2
156	Acute Tumor Lysis Syndrome Triggered by Zoledronic Acid in a Patient with Metastatic Lung Adenocarcinoma. <i>Medical Oncology</i> , 2005, 22, 203-206.	1.2	14
157	Oxaliplatin-induced immune pancytopenia. <i>Transfusion</i> , 2005, 45, 704-708.	0.8	52
158	Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. <i>Veterinary and Comparative Oncology</i> , 2005, 3, 73-80.	0.8	88
159	What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer?. <i>Colorectal Disease</i> , 2005, 7, 176-181.	0.7	37
160	Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas. <i>BJU International</i> , 2005, 95, 315-318.	1.3	15
161	Cytotoxic effects of pemetrexed in gastric cancer cells. <i>Cancer Science</i> , 2005, 96, 365-371.	1.7	29
162	Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. <i>British Journal of Cancer</i> , 2005, 92, 645-650.	2.9	66
163	Monoclonal antibody therapy of cancer. <i>Nature Biotechnology</i> , 2005, 23, 1147-1157.	9.4	1,068
164	Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. <i>Oncogene</i> , 2005, 24, 4701-4709.	2.6	99
165	Antivascular Therapy of Oral Tongue Squamous Cell Carcinoma with PTK787. <i>Laryngoscope</i> , 2005, 115, 2249-2255.	1.1	19
166	Decreased susceptibility of mast cell-deficient KitW/KitW-v mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. <i>Laboratory Investigation</i> , 2005, 85, 388-396.	1.7	68
167	Adjuvant and Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: Literature Review. <i>European Urology</i> , 2005, 48, 60-68.	0.9	59
168	The epidermal growth factor receptor as a target for colorectal cancer therapy. <i>Seminars in Oncology</i> , 2005, 32, 52-60.	0.8	84
169	Strategies to Treat Primary Unresectable Colorectal Liver Metastases. <i>Seminars in Oncology</i> , 2005, 32, 33-39.	0.8	45

#	ARTICLE	IF	CITATIONS
170	Chemoprevention Strategies for Patients with Lung Cancer in the Context of Screening. <i>Clinical Lung Cancer</i> , 2005, 7, 92-99.	1.1	10
171	Recent Advances and Future Perspectives in the Management of Lung Cancer. <i>Current Problems in Surgery</i> , 2005, 42, 548-610.	0.6	3
172	Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. <i>Gynecologic Oncology</i> , 2005, 97, 898-903.	0.6	74
173	A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemona~ve advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 98, 134-140.	0.6	6
174	Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2005, 99, 415-421.	0.6	82
175	The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. <i>Gynecologic Oncology</i> , 2005, 99, 552-556.	0.6	24
176	Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. <i>International Journal of Cancer</i> , 2005, 115, 393-402.	2.3	69
177	Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. <i>Cancer</i> , 2005, 103, 1265-1273.	2.0	116
178	VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. <i>Cancer</i> , 2005, 104, 2517-2521.	2.0	48
179	The antivasular action of physiotherapy ultrasound on murine tumors. <i>Ultrasound in Medicine and Biology</i> , 2005, 31, 1403-1410.	0.7	68
180	Novel Therapeutics in Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1632-1650.	0.7	20
181	Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005, 10, 1095-1103.	2.2	35
182	Imatinib mesylate and its potential implications for gynecologic cancers. <i>Current Treatment Options in Oncology</i> , 2005, 6, 115-120.	1.3	10
183	Clinical experience with monoclonal antibodies to epidermal growth factor receptor. <i>Current Oncology Reports</i> , 2005, 7, 96-103.	1.8	21
184	Brief Report: Towards a dietary prevention of hereditary breast cancer. <i>Cancer Causes and Control</i> , 2005, 16, 125-138.	0.8	37
185	Integrin signaling in malignant melanoma. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 195-222.	2.7	256
186	Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivasular therapy of human prostate cancer in the prostate of nude mice. <i>Prostate</i> , 2005, 65, 203-215.	1.2	34
187	Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. current status and future perspective. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 1415.	3.0	52

#	ARTICLE	IF	CITATIONS
188	Analysis of Hypoxia-Related Gene Expression in Sarcomas and Effect of Hypoxia on RNA Interference of Vascular Endothelial Cell Growth Factor A. <i>Cancer Research</i> , 2005, 65, 5881-5889.	0.4	134
189	An Increasingly Common Challenge: Management of the Complete Responder With Multi-Focal Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1799-1802.	0.8	12
190	Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. <i>Prostate Cancer and Prostatic Diseases</i> , 2005, 8, 127-132.	2.0	16
191	Pemetrexed Therapy for Malignant Pleural Mesothelioma. <i>Annals of Pharmacotherapy</i> , 2005, 39, 678-683.	0.9	3
192	Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. <i>Annals of Oncology</i> , 2005, 16, 1906-1914.	0.6	59
193	Functional CT for Quantifying Tumor Perfusion in Antiangiogenic Therapy in a Rat Model. <i>Radiology</i> , 2005, 237, 151-158.	3.6	111
194	Tumor Cavitation in Stage I Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome. <i>Radiology</i> , 2005, 237, 342-347.	3.6	84
195	Contortrostatin, a Snake Venom Disintegrin with Anti-Angiogenic and Anti-Tumor Activity. Pathophysiology of Haemostasis and Thrombosis: <i>International Journal on Haemostasis and Thrombosis Research</i> , 2005, 34, 169-176.	0.5	51
196	Life and Death Decisions: Ceramide Generation and EGF Receptor Trafficking Are Modulated by Oxidative Stress. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 119-128.	2.5	45
197	Mutant V599E-B-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors. <i>Cancer Research</i> , 2005, 65, 2412-2421.	0.4	296
198	Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. <i>British Journal of Cancer</i> , 2005, 93, 355-363.	2.9	152
199	Localization of a Substrate Binding Domain of the Human Reduced Folate Carrier to Transmembrane Domain 11 by Radioaffinity Labeling and Cysteine-substituted Accessibility Methods. <i>Journal of Biological Chemistry</i> , 2005, 280, 36206-36213.	1.6	31
200	Epidermal Growth Factor and Hypoxia-induced Expression of CXC Chemokine Receptor 4 on Non-small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-1 $\alpha$ . <i>Journal of Biological Chemistry</i> , 2005, 280, 22473-22481.	1.6	293
201	Enhanced Efficacy of Radioimmunotherapy with <sup>90</sup> Y-CHX-A <sup>3</sup> -DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478. <i>Clinical Cancer Research</i> , 2005, 11, 7080s-7086s.	3.2	76
202	Delivery of Antiangiogenic Agents for Cancer Gene Therapy. <i>Technology in Cancer Research and Treatment</i> , 2005, 4, 331-341.	0.8	5
203	The Septin-Binding Protein Anillin Is Overexpressed in Diverse Human Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 6780-6786.	3.2	78
204	Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. <i>Future Oncology</i> , 2005, 1, 733-746.	1.1	22
205	Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6838-6845.	0.8	574

#	ARTICLE	IF	CITATIONS
206	Molecular Pathology of Non-Small-Cell Lung Cancer. <i>Respiration</i> , 2005, 72, 313-330.	1.2	51
207	Antimetabolites. , 2006, , 1-18.		0
208	Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2005, 65, 5374-5379.	0.4	54
209	Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). <i>Cancer Research</i> , 2005, 65, 3328-3335.	0.4	359
210	Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity. <i>Clinical Cancer Research</i> , 2005, 11, 6390-6399.	3.2	103
211	Folate During Antifolate Chemotherapy: What We Know and Do Not Know. <i>Nutrition in Clinical Practice</i> , 2005, 20, 411-422.	1.1	28
212	Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab. <i>Oncologist</i> , 2005, 10, 282-291.	1.9	39
213	Synergy of Epidermal Growth Factor Receptor Kinase Inhibitor AG1478 and ErbB2 Kinase Inhibitor AG879 in Human Colon Carcinoma Cells Is Associated with Induction of Apoptosis. <i>Cancer Research</i> , 2005, 65, 5848-5856.	0.4	44
214	Nicotine Induces Cyclooxygenase-2 and Vascular Endothelial Growth Factor Receptor-2 in Association with Tumor-Associated Invasion and Angiogenesis in Gastric Cancer. <i>Molecular Cancer Research</i> , 2005, 3, 607-615.	1.5	108
215	Modulation of drug cytotoxicity by iressa (ZD1839) in pancreatic cancer cell lines. <i>Cancer Biology and Therapy</i> , 2005, 4, 1089-1095.	1.5	10
216	Suppression of MUC1 synthesis downregulates expression of the epidermal growth factor receptor. <i>Cancer Biology and Therapy</i> , 2005, 4, 968-973.	1.5	23
217	Erlotinib in Lung Cancer Molecular and Clinical Predictors of Outcome. <i>New England Journal of Medicine</i> , 2005, 353, 133-144.	13.9	1,787
218	Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 643-655.	3.0	1,517
219	Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non-Small-Cell Lung Cancer With Postoperative Recurrence. <i>Journal of Clinical Oncology</i> , 2005, 23, 2513-2520.	0.8	922
220	Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate. , 2005, 63, 275-300.		6
221	Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. <i>Human Pathology</i> , 2005, 36, 1127-1134.	1.1	53
222	Pemetrexed: A multitargeted antifolate. <i>Clinical Therapeutics</i> , 2005, 27, 1343-1382.	1.1	114
223	Zoledronic acid to prevent skeletal complications in cancer: Corroborating the evidence. <i>Cancer Treatment Reviews</i> , 2005, 31, 19-25.	3.4	69

#	ARTICLE	IF	CITATIONS
224	Chemoprevention in lung carcinogenesis – An overview. <i>European Journal of Cancer</i> , 2005, 41, 1990-2002.	1.3	15
225	Growth factors and their relationship to neoplastic and paraneoplastic disease. <i>European Journal of Internal Medicine</i> , 2005, 16, 83-94.	1.0	3
226	Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. <i>Progress in Lipid Research</i> , 2005, 44, 68-97.	5.3	521
227	Evolving Role of Bisphosphonates in Women Undergoing Treatment for Localized and Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 5, S54-S62.	1.1	12
228	Recent Data with Anti-EGFR Epidermal Growth Factor Receptor Antibodies and Irinotecan in Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, S81-S88.	1.0	7
229	Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. <i>Gastroenterology</i> , 2005, 128, 1642-1654.	0.6	142
230	Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. <i>Lung Cancer</i> , 2005, 47, 315-323.	0.9	33
231	Novel Therapies in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 343-367.	0.9	4
232	Tumour Oxygenation: The Importance of Hypoxia, Anemia, and Angiogenesis in Radiation Therapy. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2005, 36, 21-33.	0.1	2
233	Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells. <i>Neoplasia</i> , 2005, 7, 426-431.	2.3	51
234	Chemotherapy in Locally Advanced and Metastatic Bladder Cancer. <i>American Journal of Cancer</i> , 2005, 4, 1-13.	0.4	4
235	Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. <i>British Journal of Cancer</i> , 2005, 92, 1069-1077.	2.9	42
236	Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2005, 353, 2477-2490.	13.9	1,435
237	Plasma MIP-1 $\beta$ levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. <i>Lung Cancer</i> , 2005, 50, 393-399.	0.9	15
239	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. <i>British Journal of Cancer</i> , 2006, 95, 998-1004.	2.9	271
241	Inflammation, a Key Event in Cancer Development. <i>Molecular Cancer Research</i> , 2006, 4, 221-233.	1.5	913
242	Alteration of Pemetrexed Excretion in the Presence of Acute Renal Failure and Effusions: Presentation of a Case and Review of the Literature. <i>Cancer Investigation</i> , 2006, 24, 283-287.	0.6	24
243	Laminin $\pm$ 2 Chain-Positive Vessels and Epidermal Growth Factor in Lung Neuroendocrine Carcinoma. <i>American Journal of Pathology</i> , 2006, 168, 991-1003.	1.9	11

#	ARTICLE	IF	CITATIONS
244	Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 351-356.	1.2	34
245	Novel Therapies Targeting Signaling Pathways in Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2006, 16, 379-396.	0.4	12
246	A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 335-341.	1.2	178
247	Liver Histology and Surgical Outcomes After Preoperative Chemotherapy With Fluorouracil Plus Oxaliplatin in Colorectal Cancer Liver Metastases. <i>Journal of Clinical Oncology</i> , 2006, 24, 4983-4990.	0.8	485
248	Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6573-6584.	3.2	144
249	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. <i>Annals of Diagnostic Pathology</i> , 2006, 10, 306-315.	0.6	36
250	Update of current therapeutic options for the treatment of postmenopausal osteoporosis. <i>Clinical Therapeutics</i> , 2006, 28, 151-173.	1.1	90
251	Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?. <i>Cancer Treatment Reviews</i> , 2006, 32, 630-636.	3.4	29
252	Le point sur les anticorps autoris�s en imagerie et en immunoth�rapie. <i>Immuno-Analyse Et Biologie Specialisee</i> , 2006, 21, 255-263.	0.0	0
253	Pathology of Lung Cancer. , 2006, , 12-26.		1
255	Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Basic Science Discovery with Immediate Clinical Impact. <i>American Journal of the Medical Sciences</i> , 2006, 331, 139-149.	0.4	11
256	From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. <i>Anti-Cancer Drugs</i> , 2006, 17, 113-121.	0.7	22
257	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. <i>Current Opinion in Oncology</i> , 2006, 18, 609-614.	1.1	4
258	Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2006, 61, 529-534.	0.2	1
259	Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2006, 36, 600-603.	0.5	46
260	Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. <i>Veterinary and Comparative Oncology</i> , 2006, 4, 33-40.	0.8	33
261	High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. <i>Cancer Science</i> , 2006, 97, 642-648.	1.7	138
262	Drugs, their targets and the nature and number of drug targets. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 821-834.	21.5	702

#	ARTICLE	IF	CITATIONS
263	A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2006, 94, 964-968.	2.9	45
264	EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. <i>British Journal of Cancer</i> , 2006, 95, 1390-1395.	2.9	126
265	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. <i>Modern Pathology</i> , 2006, 19, 986-998.	2.9	17
266	Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. <i>Biomaterials</i> , 2006, 27, 1868-1875.	5.7	144
267	Polyarthrite rhumatoïde et bisphosphonates. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2006, 73, 659-664.	0.0	0
268	Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. <i>Investigational New Drugs</i> , 2006, 24, 521-527.	1.2	69
269	Biological and clinical implications of EGFR mutations in lung cancer. <i>International Journal of Clinical Oncology</i> , 2006, 11, 190-198.	1.0	194
270	A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 671-677.	1.1	18
271	Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. <i>Biomaterials</i> , 2006, 27, 5242-5251.	5.7	304
272	Differential expression of EGFR and TGF $\beta$ in VHL-mutated renal cell carcinomas of the clear cell type: implications for targeted therapeutic approaches. <i>Targeted Oncology</i> , 2006, 1, 71-78.	1.7	4
273	Second- and third-line treatments in non-small cell lung cancer. <i>Current Treatment Options in Oncology</i> , 2006, 7, 37-49.	1.3	17
274	Bisphosphonate therapy in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2006, 73, 349-354.	0.8	47
275	Is Quantitative Real-Time RT-PCR an Adjunct to Immunohistochemistry for the Evaluation of ErbB2 Status in Transitional Carcinoma of the Bladder?. <i>European Urology</i> , 2006, 49, 1035-1043.	0.9	6
276	Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy. <i>Seminars in Oncology</i> , 2006, 33, 15-49.	0.8	343
277	Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy. <i>Pharmacotherapy</i> , 2006, 26, 641-654.	1.2	33
278	Effects of a moderate-intensity static magnetic field on VEGF-A stimulated endothelial capillary tubule formation in vitro. <i>Bioelectromagnetics</i> , 2006, 27, 628-640.	0.9	47
279	A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics. <i>Cancer</i> , 2006, 107, 2760-2769.	2.0	60
280	Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. <i>Medicinal Research Reviews</i> , 2006, 26, 569-594.	5.0	122



#	ARTICLE	IF	CITATIONS
281	Theaflavin-3, 3â€²-digallate induces epidermal growth factor receptor downregulation. <i>Molecular Carcinogenesis</i> , 2006, 45, 204-212.	1.3	26
282	Using immunotherapy to target EGF in patients with NSCLC. <i>Cancer Biology and Therapy</i> , 2006, 5, 150-151.	1.5	1
283	EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1â€”Independent and HIF-1â€”Dependent Mechanisms. <i>Cancer Research</i> , 2006, 66, 3197-3204.	0.4	256
284	Clinical Pharmacology of Cyclophosphamide and Ifosfamide. <i>Current Drug Therapy</i> , 2006, 1, 55-84.	0.2	83
285	Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. <i>Cancer Biology and Therapy</i> , 2006, 5, 375-379.	1.5	137
286	Targeting Mitogen-Activated Protein Kinase/Extracellular Signalâ€”Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases. <i>Cancer Research</i> , 2006, 66, 8200-8209.	0.4	108
287	Antiangiogenic therapy in human gastrointestinal malignancies. <i>Gut</i> , 2006, 55, 1497-1511.	6.1	10
289	The changing pattern of management for hormone-refractory, metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2006, 9, 221-229.	2.0	17
290	VEGF Inhibitors in Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2006, 12, 387-394.	0.9	102
291	Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 329-336.	1.9	54
292	Second-line chemotherapy for non-small cell lung cancer. <i>Annals of Oncology</i> , 2006, 17, v68-v71.	0.6	10
293	Effect of Inhibition of Vascular Endothelial Growth Factor Signaling on Distribution of Extravasated Antibodies in Tumors. <i>Cancer Research</i> , 2006, 66, 1434-1445.	0.4	92
294	Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 952-961.	1.9	190
295	Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Nonâ€”Small Cell Lung Cancer. <i>Oncologist</i> , 2006, 11, 358-373.	1.9	60
296	The Present and Future of Angiogenesisâ€”Directed Treatments of Colorectal Cancer. <i>Oncologist</i> , 2006, 11, 992-998.	1.9	26
297	Transmembrane Domains 4, 5, 7, 8, and 10 of the Human Reduced Folate Carrier Are Important Structural or Functional Components of the Transmembrane Channel for Folate Substrates. <i>Journal of Biological Chemistry</i> , 2006, 281, 33588-33596.	1.6	26
298	Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. , 2006, , 223-268.		61
299	Antitumor Effect of 2-Methoxyestradiol in a Rat Orthotopic Brain Tumor Model. <i>Cancer Research</i> , 2006, 66, 11991-11997.	0.4	81

#	ARTICLE	IF	CITATIONS
300	Potential and Toxicity of Intravesical Pemetrexed: a Preclinical Study in Pigs. <i>Clinical Cancer Research</i> , 2006, 12, 2597-2601.	3.2	3
301	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Present and Future Role in Gastrointestinal Cancer Treatment: A Review. <i>Oncologist</i> , 2006, 11, 602-611.	1.9	29
302	Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3915-3921.	3.2	312
303	Retinal Degenerations. , 2007, , .		7
304	Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor- $\kappa$ B and nuclear factor- $\kappa$ B-regulated gene products in IFN- $\gamma$ -sensitive and IFN- $\gamma$ -resistant human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1022-1030.	1.9	152
305	Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor. <i>Clinical Cancer Research</i> , 2007, 13, 1540-1551.	3.2	102
306	The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. <i>Clinical Cancer Research</i> , 2007, 13, 1911-1925.	3.2	64
307	High-resolution imaging of the dynamic tumor cell-vascular interface in transparent zebrafish. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17406-17411.	3.3	295
308	Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. <i>British Journal of Cancer</i> , 2007, 97, 183-193.	2.9	31
309	Optimizing Anti-EGFR Strategies in Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 267-275.	0.2	0
310	Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Oncologist</i> , 2007, 12, 211-220.	1.9	44
311	Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer. <i>Chest</i> , 2007, 131, 1628-1634.	0.4	106
312	A Translational View of the Molecular Pathogenesis of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 327-343.	0.5	274
313	The Effect of Estradiol on in Vivo Tumorigenesis Is Modulated by the Human Epidermal Growth Factor Receptor 2/Phosphatidylinositol 3-Kinase/Akt1 Pathway. <i>Endocrinology</i> , 2007, 148, 1171-1180.	1.4	12
314	Derivation and Characterization of Monoclonal Antibodies Against Human Folypolyglutamate Synthetase. <i>Hybridoma</i> , 2007, 26, 155-161.	0.5	7
315	WWOX Expression in Different Histologic Types and Subtypes of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 884-891.	3.2	58
316	Fluorouracil-Based Chemotherapy in Patients with Gastrointestinal Malignancies: Influence of Nutritional Folate Status on Toxicity. <i>Journal of Chemotherapy</i> , 2007, 19, 744-749.	0.7	11
317	Molecular Basis of the Synergistic Antiangiogenic Activity of Bevacizumab and Mithramycin A. <i>Cancer Research</i> , 2007, 67, 4878-4885.	0.4	66

#	ARTICLE	IF	CITATIONS
318	New drug development in digestive neuroendocrine tumors. <i>Annals of Oncology</i> , 2007, 18, 1307-1313.	0.6	27
319	Adjuvant Chemotherapy of Stage I Non-small Cell Lung Cancer in North America. <i>Journal of Thoracic Oncology</i> , 2007, 2, S125-S127.	0.5	7
320	Erlotinib-Associated Alopecia in a Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1136-1138.	0.5	7
321	Adjuvant Use of Epidermal Growth Factor Receptor Kinase Inhibitors May Prevent Bone Metastases in Patients with Non-small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1136.	0.5	5
322	Pharmacology of Epidermal Growth Factor Inhibitors. <i>International Journal of Biological Markers</i> , 2007, 22, 24-39.	0.7	10
323	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. <i>International Journal of Biological Markers</i> , 2007, 22, 10-23.	0.7	5
325	Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study. <i>Anti-Cancer Drugs</i> , 2007, 18, 1207-1211.	0.7	9
326	Early Detection of Lung Cancer: A Call for Novel Biomarkers-Review. <i>Biotechnology and Biotechnological Equipment</i> , 2007, 21, 145-150.	0.5	2
327	Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. <i>Anti-Cancer Drugs</i> , 2007, 18, 211-218.	0.7	22
328	Overexpression of fucosyltransferase IV in A431 cell line increases cell proliferation. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1722-1730.	1.2	29
329	Expression of epidermal growth factor receptor, but not K-RAS mutations, is present in congenital cystic airway malformation/congenital pulmonary airway malformation. <i>Human Pathology</i> , 2007, 38, 1772-1778.	1.1	18
331	A Complex Pattern of Melanonychia and Onycholysis After Treatment With Pemetrexed for Lung Cancer. <i>Skinmed</i> , 2007, 6, 95-96.	0.0	8
332	The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents. <i>Molecular Cancer Research</i> , 2007, 5, 203-220.	1.5	378
333	Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. <i>Respiratory Research</i> , 2007, 8, 85.	1.4	86
334	Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1 $\alpha$ . <i>Molecular Cancer</i> , 2007, 6, 63.	7.9	55
335	An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study. <i>Biomarker Insights</i> , 2007, 2, 117727190700200.	1.0	4
336	Hypoxia and prognosis: the oxygen tension mounts. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3502.	3.0	8
337	Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S12-S14.	0.5	6

#	ARTICLE	IF	CITATIONS
338	Modification of the tumor microenvironment to enhance immunity. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3576.	3.0	43
340	Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. <i>International Journal of Cancer</i> , 2007, 120, 1579-1590.	2.3	27
341	Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. <i>Cancer</i> , 2007, 110, 2682-2690.	2.0	77
342	The Antivascular Action of Physiotherapy Ultrasound on A Murine Tumor: Role of A Microbubble Contrast Agent. <i>Ultrasound in Medicine and Biology</i> , 2007, 33, 1901-1910.	0.7	52
343	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). <i>British Journal of Cancer</i> , 2007, 97, 778-784.	2.9	198
344	A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. <i>British Journal of Cancer</i> , 2007, 97, 1618-1624.	2.9	98
345	The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). <i>British Journal of Dermatology</i> , 2007, 156, 25-33.	1.4	78
346	Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 1-14.	0.7	105
347	Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. <i>Cancer Science</i> , 2007, 98, 96-101.	1.7	86
348	Epidermal growth factor receptor mutations in lung cancers. <i>Pathology International</i> , 2007, 57, 233-244.	0.6	72
349	Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. <i>BMC Cancer</i> , 2007, 7, 199.	1.1	38
350	Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. <i>BMC Cancer</i> , 2007, 7, 74.	1.1	35
351	Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. <i>Gynecologic Oncology</i> , 2007, 106, 513-520.	0.6	77
352	Challenges for patient selection with VEGF inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 151-170.	1.1	77
353	Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 111-128.	2.7	233
354	Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 79-86.	1.7	26
356	Advances in diagnosis and treatment of malignant pleural mesothelioma. <i>Oncology Reviews</i> , 2007, 1, 91-102.	0.8	2
357	Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. <i>Targeted Oncology</i> , 2007, 2, 145-151.	1.7	3

#	ARTICLE	IF	CITATIONS
358	Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 95-101.	2.7	15
359	Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 263-270.	1.1	12
360	Endothelial and Hematopoietic Progenitor Cells (EPCs and HPCs): Hand in Hand Fate Determining Partners for Cancer Cells. <i>Stem Cell Reviews and Reports</i> , 2008, 4, 169-177.	5.6	48
361	Bisphosphonate treatment and radiotherapy in metastatic breast cancer. <i>Medical Oncology</i> , 2008, 25, 350-355.	1.2	17
362	EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2008, 7, 440-446.	0.1	1
363	Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. <i>Journal of Gastroenterology</i> , 2008, 43, 959-966.	2.3	47
364	Natural products and colon cancer: current status and future prospects. <i>Drug Development Research</i> , 2008, 69, 460-471.	1.4	149
365	Rational identification of a novel peptide for targeting nanocarriers to 9L glioma. <i>Journal of Biomedical Materials Research - Part A</i> , 2008, 87A, 728-738.	2.1	7
366	A Fraâ€¢-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. <i>Journal of Cellular Physiology</i> , 2008, 216, 405-412.	2.0	43
367	Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 21-30.	2.0	40
368	EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. <i>Oncogene</i> , 2008, 27, 4336-4343.	2.6	72
369	Catch of the day: zebrafish as a human cancer model. <i>Oncogene</i> , 2008, 27, 4509-4520.	2.6	181
370	A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 1215-1233.	1.2	45
371	Soy consumption reduces the risk of nonâ€¢smallâ€¢cell lung cancers with <i>epidermal growth factor receptor</i> mutations among Japanese. <i>Cancer Science</i> , 2008, 99, 1202-1208.	1.7	28
372	New Data Integrating Multitargeted Antifolates into Treatment of First-line and Relapsed Nonâ€¢Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, S122-S128.	1.1	10
373	Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells. <i>Oral Oncology</i> , 2008, 44, 361-368.	0.8	18
374	Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. <i>Oral Oncology</i> , 2008, 44, 857-869.	0.8	227
375	Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. <i>Lung Cancer</i> , 2008, 60, 271-276.	0.9	32

#	ARTICLE	IF	CITATIONS
376	Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?. Lung Cancer, 2008, 61, 73-81.	0.9	22
377	Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients. Lung Cancer, 2008, 61, 328-339.	0.9	45
378	Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis. , 2008, , 1725-1742.		6
379	EGFR Signaling Networks in Cancer Therapy. , 2008, , .		11
380	The Disruption of Murine Tumor Neovasculature by Low-intensity Ultrasoundâ€”Comparison Between 1- and 3-MHz Sonication Frequencies. Academic Radiology, 2008, 15, 1133-1141.	1.3	54
381	Oxidants in Biology. , 2008, , .		11
382	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. , 2008, , .		3
383	Curcumin and cancer: An â€œold-ageâ€•disease with an â€œage-oldâ€•solution. Cancer Letters, 2008, 267, 133-164.	3.2	951
384	The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab. European Journal of Cancer, 2008, 44, 912-920.	1.3	58
385	Imaging Epidermal Growth Factor Receptor Expression <i>In vivo</i> : Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe. Clinical Cancer Research, 2008, 14, 731-741.	3.2	183
386	Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer: Focus on Inhibition of Epidermal Growth Factor Receptor. Seminars in Thoracic and Cardiovascular Surgery, 2008, 20, 217-223.	0.4	9
387	Heme Oxygenase-1 Prevents Airway Mucus Hypersecretion Induced by Cigarette Smoke in Rodents and Humans. American Journal of Pathology, 2008, 173, 981-992.	1.9	40
388	Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Antiâ€•Vascular Endothelial Growth Factor A Therapy. Neoplasia, 2008, 10, 613-623.	2.3	69
390	Roles of Integrins in Tumor Angiogenesis and Lymphangiogenesis. Lymphatic Research and Biology, 2008, 6, 155-163.	0.5	82
391	Synthesis and Discovery of High Affinity Folate Receptor-Specific Glycinamide Ribonucleotide Formyltransferase Inhibitors with Antitumor Activity. Journal of Medicinal Chemistry, 2008, 51, 5052-5063.	2.9	70
392	Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leukemia and Lymphoma, 2008, 49, 410-426.	0.6	76
393	Role of Lysine 411 in Substrate Carboxyl Group Binding to the Human Reduced Folate Carrier, as Determined by Site-Directed Mutagenesis and Affinity Inhibition. Molecular Pharmacology, 2008, 73, 1274-1281.	1.0	16
394	Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy. Oncologist, 2008, 13, 911-920.	1.9	135

#	ARTICLE	IF	CITATIONS
395	Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7947-7955.	3.2	16
396	Suppression of proHB-EGF Carboxy-Terminal Fragment Nuclear Translocation: A New Molecular Target Therapy for Gastric Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3956-3965.	3.2	28
397	Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 972-979.	1.9	23
398	Megaloblastic Anemia Due To Intrathecal Methotrexate. <i>Medical Journal of the Trakya University</i> , 2008, , .	0.0	1
399	CXCL12 chemokine genotypes as predictive biomarkers of ovarian cancer outcome. <i>Molecular Medicine Reports</i> , 2008, 2, 103-6.	1.1	3
400	Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. <i>Molecular Medicine Reports</i> , 2008, 1, 641-6.	1.1	46
401	Targeting cancer cells by synthetic lethality. <i>Cell Cycle</i> , 2008, 7, 2987-2990.	1.3	21
402	Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. <i>British Journal of Cancer</i> , 2008, 98, 154-160.	2.9	100
403	Mechanisms of Disease: signal transduction in lung carcinogenesisâ€”a comparison of smokers and never-smokers. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 610-618.	4.3	22
404	Regulation of Gene Expression in the Tumor Environment. , 2008, , .		0
405	Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. <i>European Respiratory Journal</i> , 2008, 31, 1334-1356.	3.1	475
406	Tumor necrosis factor inhibits ligand-stimulated EGF receptor activation through a TNF receptor 1-dependent mechanism. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G285-G293.	1.6	22
407	Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 502-508.	3.2	111
408	Chapter 5 Structure and Function of the Reduced Folate Carrier. <i>Vitamins and Hormones</i> , 2008, 79, 145-184.	0.7	72
409	Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors. <i>Toxicologic Pathology</i> , 2008, 36, 905-916.	0.9	84
410	EGF-conjugated near-infrared quantum dots as nanoprobes for in-vivo imaging of EGFR expression. <i>Proceedings of SPIE</i> , 2008, , .	0.8	3
411	Vascular Permeability during Antiangiogenesis Treatment: MR Imaging Assay Results as Biomarker for Subsequent Tumor Growth in Rats. <i>Radiology</i> , 2008, 247, 391-399.	3.6	56
414	The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplexâ€”interactive agents. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 880-889.	1.9	159

#	ARTICLE	IF	CITATIONS
415	Zoledronic acid for cancer therapy-induced and postmenopausal bone loss. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1013-1028.	0.9	5
416	Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma. <i>Cancer Biology and Therapy</i> , 2008, 7, 333-339.	1.5	78
417	Diagnostic Markers for Early Detection of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1065-1072.	3.2	371
419	Public Health Significance of Supplementation or Fortification of Grain Products with Folic Acid. <i>Food and Nutrition Bulletin</i> , 2008, 29, S173-S176.	0.5	6
420	Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. <i>Biologics: Targets and Therapy</i> , 2008, 2, 517.	3.0	11
421	Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 445-451.	1.3	50
422	Targeting thymidylate synthase by antifolate drugs for the treatment of cancer. , 2008, , 198-226.		3
423	Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. <i>Frontiers in Bioscience - Scholar</i> , 2009, S1, 304-318.	0.8	13
424	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. <i>Biologics: Targets and Therapy</i> , 0, , 215.	3.0	12
425	Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. <i>Pharmacogenomics and Personalized Medicine</i> , 2009, 2, 21.	0.4	0
426	Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC. <i>Oncologist</i> , 2009, 14, 399-411.	1.9	86
427	Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies. <i>Breast Care</i> , 2009, 4, 46-50.	0.8	0
428	Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer. <i>Upsala Journal of Medical Sciences</i> , 2009, 114, 160-164.	0.4	17
429	Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. <i>Acta Radiologica</i> , 2009, 50, 1095-1103.	0.5	33
430	Reconstitution of Amphiregulinâ€“Epidermal Growth Factor Receptor Signaling in Lung Squamous Cell Carcinomas Activates PTHrP Gene Expression and Contributes to Cancer-Mediated Diseases of the Bone. <i>Molecular Cancer Research</i> , 2009, 7, 1714-1728.	1.5	18
431	Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. <i>European Journal of Pharmacology</i> , 2009, 602, 124-131.	1.7	36
432	Targeted radionuclide therapy in head and neck cancer. <i>Head and Neck</i> , 2010, 32, 666-678.	0.9	11
433	Targeted therapies in squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2009, 115, 922-935.	2.0	122



#	ARTICLE	IF	CITATIONS
434	Fighting Cancer: From the Bench to Bedside Using Second Generation Cationic Liposomal Therapeutics. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 411-429.	1.6	88
435	Lung cancer A549 cells migrate directionally in DC electric fields with polarized and activated EGFRs. <i>Bioelectromagnetics</i> , 2009, 30, 29-35.	0.9	64
436	Extended liver resection after preoperative chemotherapy: influence on regeneration and endoplasmic reticulum stress response. <i>Langenbeck's Archives of Surgery</i> , 2009, 394, 681-688.	0.8	5
437	EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 771-782.	1.2	38
438	Development and validation of an improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 2451-2456.	1.2	20
439	Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 187-190.	1.1	9
440	p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047. <i>Cancer Letters</i> , 2009, 277, 108-113.	3.2	33
442	Effects of silencing of HER2/neu gene in anti-BPDE-transformed cells. <i>Toxicology in Vitro</i> , 2009, 23, 53-59.	1.1	7
443	Field Treatment of Actinic Keratoses - Focus on COX-2-Inhibitors. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 55-58.	0.2	5
444	Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2653-2659.	0.8	281
445	Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. <i>Lung Cancer</i> , 2009, 65, 25-33.	0.9	47
446	The Role of Cetuximab in the Management of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, 230-238.	1.1	11
447	Updated Clinical Information on Multitargeted Antifolates in Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, S35-S40.	1.1	26
448	KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. <i>Journal of Translational Medicine</i> , 2009, 7, 63.	1.8	19
449	Pathophysiology of COPD. , 2009, , 425-442.		2
450	Novel Therapeutic Targets. <i>Cancer Treatment and Research</i> , 2009, 149, 63-84.	0.2	2
451	Les grandes étapes de la personnalisation des traitements en oncologie : spécificité du mode d'action du pemetrexed. <i>Revue Des Maladies Respiratoires Actualites</i> , 2009, 1, S17-S21.	0.0	0
452	Development and Validation of a Protein-based Signature for the Detection of Ovarian Cancer. <i>Clinics in Laboratory Medicine</i> , 2009, 29, 47-55.	0.7	49

#	ARTICLE	IF	CITATIONS
453	New therapeutic agents in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 44-53.	0.9	17
454	The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 58-60.	1.0	5
455	The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action. <i>Current Drug Targets</i> , 2010, 11, 37-47.	1.0	45
456	Genetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1887-1893.	0.5	31
457	Prognostic value of epidermal growth factor receptor expression in operable non-small cell lung carcinoma. <i>Multidisciplinary Respiratory Medicine</i> , 2010, 5, 305.	0.6	8
458	Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non-small Cell Lung Cancer?. <i>Journal of Thoracic Oncology</i> , 2010, 5, 551-553.	0.5	9
459	Synthesis and applications of magnetic nanoparticles for biorecognition and point of care medical diagnostics. <i>Nanotechnology</i> , 2010, 21, 442001.	1.3	117
460	Identification and characterization of Ch806 mimotopes. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1481-1487.	2.0	17
461	Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 483-495.	1.4	46
462	Expression of EGFR, HER-2/neu and KIT in germ cell tumours. <i>Clinical and Translational Oncology</i> , 2010, 12, 443-449.	1.2	14
463	Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2010, 22, 27-31.	0.7	5
464	Loading of VEGF to the heparin cross-linked demineralized bone matrix improves vascularization of the scaffold. <i>Journal of Materials Science: Materials in Medicine</i> , 2010, 21, 309-317.	1.7	51
465	Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 141-149.	1.7	65
466	Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging. <i>Journal of Neuro-Oncology</i> , 2010, 100, 17-29.	1.4	51
467	The Evolving Role of Bone-Conserving Therapy in Patients With Breast Cancer. <i>Seminars in Oncology</i> , 2010, 37, S12-S19.	0.8	5
468	A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 8-12.	1.1	22
469	Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. <i>BMC Cancer</i> , 2010, 10, 10.	1.1	120
470	Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. <i>BMC Cancer</i> , 2010, 10, 50.	1.1	225

#	ARTICLE	IF	CITATIONS
471	The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 117, 109-116.	0.6	100
472	Furano- $\epsilon$ -naphthoquinone inhibits EGFR signaling associated with G <sub>2</sub> /M cell cycle arrest and apoptosis in A549 cells. <i>Cell Biochemistry and Function</i> , 2010, 28, 695-705.	1.4	18
473	Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation. <i>BMC Gastroenterology</i> , 2010, 10, 83.	0.8	21
474	Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. <i>Journal of Nucleic Acids Investigation</i> , 2010, 1, 10.	0.5	1
475	Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges. <i>Journal of Oncology</i> , 2010, 2010, 1-20.	0.6	108
476	Cancer chemotherapy: targeting folic acid synthesis. <i>Cancer Management and Research</i> , 2010, , 293.	0.9	11
477	The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S1166.	0.4	0
478	Imaging Cycling Tumor Hypoxia. <i>Cancer Research</i> , 2010, 70, 10019-10023.	0.4	183
479	Molecular imaging agents: impact on diagnosis and therapeutics in oncology. <i>Expert Reviews in Molecular Medicine</i> , 2010, 12, e20.	1.6	28
480	Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2. <i>MAbs</i> , 2010, 2, 199-208.	2.6	57
481	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2363-2389.	0.9	19
482	Treatment of Colorectal Cancer. <i>Cancer Metastasis - Biology and Treatment</i> , 2010, , 359-388.	0.1	0
483	Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. <i>Lung Cancer</i> , 2010, 68, 375-382.	0.9	68
484	Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. <i>Translational Research</i> , 2010, 156, 98-105.	2.2	27
485	Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. <i>Journal of Hematology and Oncology</i> , 2010, 3, 18.	6.9	12
486	Comparison of Patient Outcomes According to Histology Among Pemetrexed-Treated Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer in Two Phase II Trials. <i>Clinical Lung Cancer</i> , 2010, 11, 126-131.	1.1	20
487	Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. <i>Life Sciences</i> , 2010, 86, 207-213.	2.0	19
488	Understanding the problem of inadequately staging early ovarian cancer. <i>European Journal of Cancer</i> , 2010, 46, 880-884.	1.3	45

#	ARTICLE	IF	CITATIONS
489	Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 157-163.	0.8	15
491	Drug-DNA Interaction Protocols. <i>Methods in Molecular Biology</i> , 2010, , .	0.4	13
493	Epidermal Growth Factor Receptor Signaling in Nonsmall Cell Lung Cancer. <i>Cancer Investigation</i> , 2010, 28, 515-525.	0.6	20
494	Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-“Small Cell Lung Cancer Growth and Metastasis. <i>Cancer Prevention Research</i> , 2011, 4, 65-75.	0.7	121
495	Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using Target Selection Criteria (TASC): A Novel Target Identification Tool. <i>Translational Oncology</i> , 2011, 4, 71-82.	1.7	70
496	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. <i>Cancer Treatment Reviews</i> , 2011, 37, 533-542.	3.4	31
497	A phase I/II study of neoadjuvant chemotherapy with Pemetrexed (Alimta) in rectal cancer. <i>European Journal of Surgical Oncology</i> , 2011, 37, 583-588.	0.5	7
498	AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 297-304.	1.9	23
499	Pharmacokinetic evaluation of pemetrexed. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 919-928.	1.5	19
500	Optimal integration of EGFR inhibitors in advanced colorectal cancer. <i>Community Oncology</i> , 2011, 8, 155-162.	0.2	0
501	Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1714.	3.0	8
502	Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model. <i>Diabetes and Metabolism Journal</i> , 2011, 35, 130.	1.8	17
503	Genome-Scale Screen for DNA Methylation-Based Detection Markers for Ovarian Cancer. <i>PLoS ONE</i> , 2011, 6, e28141.	1.1	65
504	EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. <i>Oncology Reports</i> , 2011, 27, 880-90.	1.2	10
505	Unique <i>p53</i> and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. <i>Cancer Science</i> , 2011, 102, 282-287.	1.7	63
506	Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011, 122, 495-500.	0.6	105
507	Solitary skin metastasis from sarcomatoid carcinoma of the bladder: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 484.	0.4	2
508	Zoledronate Inhibits Intimal Hyperplasia in Balloon-injured Rat Carotid Artery. <i>European Journal of Vascular and Endovascular Surgery</i> , 2011, 41, 288-293.	0.8	12

#	ARTICLE	IF	CITATIONS
509	EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy. <i>Annals of Surgical Oncology</i> , 2011, 18, 2952-2960.	0.7	51
510	Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. <i>Investigational New Drugs</i> , 2011, 29, 963-970.	1.2	13
511	Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis. <i>Journal of Orthopaedic Science</i> , 2011, 16, 443-450.	0.5	3
512	A Novel Magneto-fluorescent Nano-bioprobes for Cancer Cell Targeting, Imaging and Collection. <i>Applied Biochemistry and Biotechnology</i> , 2011, 163, 813-825.	1.4	20
513	<sup>18</sup> F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. <i>Annals of Nuclear Medicine</i> , 2011, 25, 625-633.	1.2	88
514	Large cell carcinoma of the lung – a vanishing entity?. <i>Memo - Magazine of European Medical Oncology</i> , 2011, 4, 4-9.	0.3	1
515	Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer. <i>BMC Cancer</i> , 2011, 11, 289.	1.1	11
516	New pemetrexed-peptide conjugates: synthesis, characterization and <i>in vitro</i> cytostatic effect on non-small cell lung carcinoma (NCI-H358) and human leukemia (HL-60) cells. <i>Journal of Peptide Science</i> , 2011, 17, 805-811.	0.8	15
517	Zoledronic acid use in cancer patients. <i>Cancer</i> , 2011, 117, 11-23.	2.0	46
518	Targeted Therapies for Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 512-527.	1.0	91
519	Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights. <i>Respiration</i> , 2011, 81, 265-284.	1.2	213
520	Effect of Hedyotis Diffusa Willd extract on tumor angiogenesis. <i>Molecular Medicine Reports</i> , 2011, 4, 1283-8.	1.1	43
521	Clinical relevance of epidermal growth factor receptor (EGFR) alterations in human pancreatic tumors. <i>Oncology Reports</i> , 2011, 26, 315-20.	1.2	5
522	Genetic profiling and ovarian cancer therapy (Review). <i>Molecular Medicine Reports</i> , 2011, 4, 771-7.	1.1	25
523	Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1091-1094.	0.5	37
524	Vascular endothelial growth factor expression in low and high grade b-cell non-hodgkin's lymphomas. <i>Turk Patoloji Dergisi</i> , 2011, 27, 204.	0.1	0
525	Identification of Potent EGFR Inhibitors from TCM Database@Taiwan. <i>PLoS Computational Biology</i> , 2011, 7, e1002189.	1.5	85
526	LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort. <i>Drug Discoveries and Therapeutics</i> , 2012, , .	0.6	5

#	ARTICLE	IF	CITATIONS
527	Anti-Tumor Monoclonal Antibodies in Conjunction with $\beta$ -Glucans: A Novel Anti- Cancer Immunotherapy. <i>Current Medicinal Chemistry</i> , 2012, 19, 4298-4305.	1.2	22
528	Pemetrexed disodium in ovarian cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 437-449.	1.9	7
529	Electron Paramagnetic Resonance Imaging of Tumor pO <sub>2</sub> . <i>Radiation Research</i> , 2012, 177, 376-386.	0.7	61
530	Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. <i>Cell Death and Disease</i> , 2012, 3, e252-e252.	2.7	68
531	Inhibition of TGF- $\beta$ 2 Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor-Targeted Therapy. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2429-2439.	1.9	66
532	Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. <i>Chemotherapy</i> , 2012, 58, 84-88.	0.8	22
533	A Miniaturized Ligand Binding Assay for EGFR. <i>International Journal of Proteomics</i> , 2012, 2012, 1-5.	2.0	1
534	EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration. <i>International Journal of Hepatology</i> , 2012, 2012, 1-9.	0.4	28
535	Current treatment practices for essential thrombocythemia: survey results from European hematologists/oncologists. <i>Hematology</i> , 2012, 17, 187-192.	0.7	2
536	Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence. <i>Cancer Biomarkers</i> , 2012, 11, 59-73.	0.8	10
537	THREE-YEAR FOLLOW-UP OF A PILOT STUDY OF RANIBIZUMAB COMBINED WITH PROTON BEAM IRRADIATION AS TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2012, 32, 956-966.	1.0	15
538	Directed Therapies in Lung Cancer: New Hope?. <i>Archivos De Bronconeumologia</i> , 2012, 48, 367-371.	0.4	5
539	Terapias dirigidas en el cncer de pulmn:  una nueva esperanza?. <i>Archivos De Bronconeumologia</i> , 2012, 48, 367-371.	0.4	6
540	Reduced Folate Carrier Independent Internalization of PEGylated Pemetrexed: A Potential Nanomedicinal Approach for Breast Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2012, 9, 2828-2843.	2.3	22
541	Docetaxel combined with targeted therapies in metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 387-396.	3.4	14
542	The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. <i>Cancer Epidemiology</i> , 2012, 36, 490-496.	0.8	76
543	Association of epidermal growth factor receptor gene polymorphisms with advanced endometriosis in a Korean population. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 164, 196-199.	0.5	3
544	Effects of Pien Tze Huang (%ä»”ç™€) on angiogenesis in vivo and in vitro. <i>Chinese Journal of Integrative Medicine</i> , 2012, 18, 431-436.	0.7	35

#	ARTICLE	IF	CITATIONS
545	Clinical implications of biological markers in pancreatic ductal adenocarcinoma. <i>Surgical Oncology</i> , 2012, 21, e171-e182.	0.8	17
546	MENA Is a Transcriptional Target of the Wnt/Beta-Catenin Pathway. <i>PLoS ONE</i> , 2012, 7, e37013.	1.1	16
547	Mucosal Restitution and Repair. , 2012, , 1147-1168.		4
548	Molecular Ultrasound Imaging Using a Targeted Contrast Agent for Assessing Early Tumor Response to Antiangiogenic Therapy. <i>Journal of Ultrasound in Medicine</i> , 2012, 31, 1543-1550.	0.8	52
549	Therapeutic Targeting of the Epidermal Growth Factor Receptor in Human Cancer. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 31-50.	0.2	59
550	Recent advances in stealth coating of nanoparticle drug delivery systems. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2012, 4, 219-233.	3.3	393
551	The coffee diterpene kahweol inhibits metastasis by modulating expressions of MMPs and VEGF via STAT3 inactivation. <i>Food Chemistry</i> , 2012, 133, 1521-1529.	4.2	16
552	PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 84-98.	2.0	10
553	Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. <i>Annals of Hematology</i> , 2012, 91, 527-532.	0.8	4
554	Radiation necrosis following treatment of high grade glioma—a review of the literature and current understanding. <i>Acta Neurochirurgica</i> , 2012, 154, 191-201.	0.9	116
555	Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1 $\alpha$ . <i>International Journal of Cancer</i> , 2013, 132, 29-41.	2.3	35
556	Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. <i>Molecular Carcinogenesis</i> , 2013, 52, 183-194.	1.3	30
557	Ependymoma in children: molecular considerations and therapeutic insights. <i>Clinical and Translational Oncology</i> , 2013, 15, 759-765.	1.2	12
558	The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. <i>BMC Cancer</i> , 2013, 13, 43.	1.1	28
560	In vivo characterization of <sup>68</sup> Ga-NOTA-VEGF121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 198-206.	3.3	19
561	Targeting Receptor Tyrosine Kinases in Solid Tumors. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 685-703.	0.6	8
562	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. <i>Cancer Treatment Reviews</i> , 2013, 39, 839-850.	3.4	100
563	Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. <i>Oncogene</i> , 2013, 32, 27-38.	2.6	114

#	ARTICLE	IF	CITATIONS
564	Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. <i>Journal of Proteomics</i> , 2013, 89, 165-178.	1.2	69
565	Effect of Local vs Systemic Bisphosphonate Delivery on Dental Implant Fixation in a Model of Osteonecrosis of the Jaw. <i>Journal of Dental Research</i> , 2013, 92, 279-283.	2.5	78
566	Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis. <i>Respirology</i> , 2013, 18, 131-139.	1.3	14
567	Complications of thermal ablation of hepatic tumours: Comparison of radiofrequency and microwave ablative techniques. <i>Clinical Radiology</i> , 2013, 68, 608-615.	0.5	78
568	The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2013, 128, 391-396.	0.6	56
569	The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 231-235.	0.9	16
570	Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 428-434.	0.9	9
571	Development and Binding Mode Assessment of N-[4-[2-Propyn-1-yl]-(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[quinazolin-6-yl]amino] Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5446-5455.	2.9	15
572	Pralatrexate Pharmacology and Clinical Development. <i>Clinical Cancer Research</i> , 2013, 19, 6657-6661.	3.2	35
573	<i>Patrinia scabiosaefolia</i> inhibits colorectal cancer growth through suppression of tumor angiogenesis. <i>Oncology Reports</i> , 2013, 30, 1439-1443.	1.2	27
574	Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts. <i>Growth Factors</i> , 2013, 31, 154-164.	0.5	3
575	Effect of Folic Acid and Vitamin B <sub>12</sub> on Pemetrexed Antifolate Chemotherapy in Nutrient Lung Cancer Cells. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	16
576	Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 143-151.	1.4	68
577	Acidity Generated by the Tumor Microenvironment Drives Local Invasion. <i>Cancer Research</i> , 2013, 73, 1524-1535.	0.4	1,036
578	The current state of pemetrexed in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1201-1210.	1.9	2
579	Clinical Significance of Amyloid Precursor Protein in Patients with Testicular Germ Cell Tumor. <i>Advances in Urology</i> , 2013, 2013, 1-6.	0.6	7
580	A Hybrid Model of the Role of VEGF Binding in Endothelial Cell Migration and Capillary Formation. <i>Frontiers in Oncology</i> , 2013, 3, 102.	1.3	13
581	Constitutive proteasomal degradation of TWIST-1 in epithelial ovarian cancer stem cells impacts differentiation and metastatic potential. <i>Oncogene</i> , 2013, 32, 39-49.	2.6	67



#	ARTICLE	IF	CITATIONS
582	Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary Carcinogenesis. <i>Cancer Prevention Research</i> , 2013, 6, 448-454.	0.7	11
583	Exploratory study on the correlation between 14 lung cancer-related gene expression and specific clinical characteristics of NSCLC patients. <i>Molecular and Clinical Oncology</i> , 2013, 1, 887-893.	0.4	6
584	Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer. <i>Cancer Biology and Therapy</i> , 2013, 14, 39-44.	1.5	4
585	Novel radioisotope-based nanomedical approaches. <i>European Journal of Nanomedicine</i> , 2013, 5, .	0.6	5
586	IL-33/IL-31 axis: A new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 2673-2676.	1.2	19
587	Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1308-1316.	0.5	32
588	Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. <i>Oncology Reports</i> , 2013, 29, 260-268.	1.2	21
589	Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non-Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501). <i>Journal of Thoracic Oncology</i> , 2013, 8, 1075-1083.	0.5	16
590	Hedyotis diffusa Willd extract suppresses Sonic hedgehog signaling leading to the inhibition of colorectal cancer angiogenesis. <i>International Journal of Oncology</i> , 2013, 42, 651-656.	1.4	56
591	Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways. <i>Oncology Reports</i> , 2013, 30, 1701-1706.	1.2	33
592	Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. <i>Oncology Reports</i> , 2013, 29, 1285-1292.	1.2	173
594	Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival. <i>Korean Journal of Radiology</i> , 2013, 14, 375.	1.5	28
595	Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 427.	1.0	19
596	HER-3 expression in HER-2-amplified breast carcinoma. <i>Wspolczesna Onkologia</i> , 2013, 5, 446-449.	0.7	3
597	Pulmonary pre-invasive disease. , 0, , 889-944.		2
598	Squamous cell carcinoma of the lung. , 0, , 1093-1113.		0
599	Lung Cancer in 2013: State of the Art Therapy for Metastatic Disease. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 339-346.	1.8	8
600	Effective Therapeutic Approach for Head and Neck Cancer by an Engineered Minibody Targeting the EGFR Receptor. <i>PLoS ONE</i> , 2014, 9, e113442.	1.1	12

#	ARTICLE	IF	CITATIONS
601	Type II cGMP-dependent protein kinase inhibits ligand-induced activation of EGFR in gastric cancer cells. <i>Molecular Medicine Reports</i> , 2014, 9, 1405-1409.	1.1	10
602	Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality. <i>World Journal of Gastroenterology</i> , 2014, 20, 15049.	1.4	74
603	Combination of Cetuximab and Rapamycin Enhances the Therapeutic Efficacy in Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2014, 13, 377-385.	0.8	17
604	Lung Injury and Lung Cancer Caused by Cigarette Smoke-Induced Oxidative Stress: Molecular Mechanisms and Therapeutic Opportunities Involving the Ceramide-Generating Machinery and Epidermal Growth Factor Receptor. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 2149-2174.	2.5	83
605	Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors. <i>Journal of International Medical Research</i> , 2014, 42, 191-197.	0.4	12
606	Luminescent-Morphological Features of Mouse Spleen after Acupuncture. <i>Bulletin of Experimental Biology and Medicine</i> , 2014, 157, 816-820.	0.3	1
607	Cytoplasmic EGFR Staining and Gene Amplification in Glottic Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 674-680.	0.6	8
608	Does Modality of Adjuvant Chemotherapy After Interval Surgical Debulking Matter in Epithelial Ovarian Cancer?: An Exploratory Analysis. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 461-467.	1.2	7
609	Effects of the administration of epidermal growth factor receptor specific inhibitor cetuximab, alone and in combination with cisplatin, on proliferation and apoptosis of Hep-2 laryngeal cancer cells. <i>Journal of Laryngology and Otology</i> , 2014, 128, 902-908.	0.4	5
610	Electrochemical preparation of sodium dodecylsulfate doped over-oxidized polypyrrole/multi-walled carbon nanotube composite on glassy carbon electrode and its application on sensitive and selective determination of anticancer drug: Pemetrexed. <i>Talanta</i> , 2014, 119, 248-254.	2.9	49
611	Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 330-338.	1.1	10
612	Phase I Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2014, 21, 1616-1623.	0.7	60
613	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 300-313.	2.0	68
614	Inflammatory Angiogenesis and the Tumor Microenvironment as Targets for Cancer Therapy and Prevention. <i>Cancer Treatment and Research</i> , 2014, 159, 401-426.	0.2	33
615	Advances in Nutrition and Cancer. <i>Cancer Treatment and Research</i> , 2014, , .	0.2	11
616	Post-Treatment Imaging Changes in Primary Brain Tumors. <i>Current Oncology Reports</i> , 2014, 16, 397.	1.8	31
617	Dual VEGF/VEGFR inhibition in advanced solid malignancies. <i>Cancer Biology and Therapy</i> , 2014, 15, 975-981.	1.5	19
618	Platelet Effects on Ovarian Cancer. <i>Seminars in Oncology</i> , 2014, 41, 378-384.	0.8	48

#	ARTICLE	IF	CITATIONS
619	Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma. <i>Journal of Visualized Experiments</i> , 2014, , e51638.	0.2	8
620	Pemetrexed in non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2014, 3, 273-285.	1.5	1
621	Livistona chinensis seeds inhibit hepatocellular carcinoma angiogenesis in vivo via suppression of the Notch pathway. <i>Oncology Reports</i> , 2014, 31, 1723-1728.	1.2	21
623	Characterization of EGFR family gene aberrations in cholangiocarcinoma. <i>Oncology Reports</i> , 2014, 32, 700-708.	1.2	47
624	Effect of Combined Bevacizumab and Temozolomide Treatment on Intramedullary Spinal Cord Tumor. <i>Spine</i> , 2014, 39, E65-E73.	1.0	12
625	Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR. <i>Oncotarget</i> , 2015, 6, 6749-6761.	0.8	13
626	Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0116977.	1.1	28
627	Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0117781.	1.1	16
628	Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations. <i>PLoS ONE</i> , 2015, 10, e0142306.	1.1	28
629	A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. <i>Cell Death and Disease</i> , 2015, 6, e1686-e1686.	2.7	59
630	Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1383-1388.	0.8	78
631	Total alkaloids of <i>Rubus alceifolius</i> Poir inhibit tumor angiogenesis through suppression of the Notch signaling pathway in a mouse model of hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2015, 11, 357-361.	1.1	10
632	Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E7276-85.	3.3	84
633	Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. <i>Clinical Lung Cancer</i> , 2015, 16, 252-261.	1.1	27
634	<i>Kras</i> , <i>Egfr</i> , and <i>Tp53</i> Mutations in B6C3F1/N Mouse and F344/NTac Rat Alveolar/Bronchiolar Carcinomas Resulting from Chronic Inhalation Exposure to Cobalt Metal. <i>Toxicologic Pathology</i> , 2015, 43, 872-882.	0.9	14
635	Mechanisms of action of therapeutic antibodies for cancer. <i>Molecular Immunology</i> , 2015, 67, 28-45.	1.0	136
636	Bear bile powder inhibits angiogenesis in vivo and in vitro. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 369-375.	0.7	7
637	Histochemical evidence of zoledronate inhibiting c-src expression and interfering with CD44/OPN-mediated osteoclast adhesion in the tibiae of mice. <i>Journal of Molecular Histology</i> , 2015, 46, 313-323.	1.0	7

#	ARTICLE	IF	CITATIONS
639	Pattern recognition of HER-1 in biological fluids using stochastic sensing. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 30, 283-285.	2.5	9
640	Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: Role of $\beta$ - $\gamma$ imaging in determining optimal window. <i>Nuclear Medicine and Biology</i> , 2015, 42, 923-930.	0.3	11
642	Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors. <i>Scientific Reports</i> , 2014, 4, 5868.	1.6	37
643	Possible molecular targets for therapeutic applications of caffeic acid phenethyl ester in inflammation and cancer. <i>Journal of Food and Drug Analysis</i> , 2015, 23, 11-18.	0.9	43
644	Epidermal growth factor receptor inhibition by anti-CD147 therapy in cutaneous squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 247-252.	0.9	7
645	Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, 9, 461.	1.0	5
646	Correlations between EGFR gene polymorphisms and pleural metastasis of lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5257-5270.	1.0	7
647	Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. <i>World Journal of Gastroenterology</i> , 2016, 22, 7692.	1.4	109
648	SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 485-495.	1.1	75
650	Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma. <i>Molecular Cancer Research</i> , 0, , .	1.5	0
651	Arginine dependence of tumor cells: targeting a chink in cancer's armor. <i>Oncogene</i> , 2016, 35, 4957-4972.	2.6	195
652	Emerging targeted therapies for glioma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 441-452.	1.0	45
653	Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 31636.	1.6	10
654	Liver Metastases From Noncolorectal Malignancies (Neuroendocrine Tumor, Sarcoma, Melanoma,) Tj ETQq1 1 0.784314 rgBT /Overlook	1.0	7
655	Brief exposure to preoperative bevacizumab reveals a TGF $\beta$ signature predictive of response in HER2-negative breast cancers. <i>International Journal of Cancer</i> , 2016, 138, 747-757.	2.3	16
656	Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. <i>Molecular Imaging and Biology</i> , 2016, 18, 807-819.	1.3	47
658	Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 133-141.	1.1	10
659	Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma. <i>Molecular Cancer Research</i> , 2016, 14, 448-457.	1.5	28

#	ARTICLE	IF	CITATIONS
660	GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 251-263.	1.9	24
661	Phase I/II Randomized Study of Proton Beam with Anti-VEGF Vascular Endothelial Growth Factor for Exudative Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2017, 1, 217-226.	1.2	6
662	Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. <i>Chemistry and Biodiversity</i> , 2017, 14, e1600372.	1.0	15
664	Development and Evaluation of 18F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC. <i>Scientific Reports</i> , 2017, 7, 3121.	1.6	22
665	Dual Functional Mesoporous Silicon Nanoparticles Enhance the Radiosensitivity of VPA in Glioblastoma. <i>Translational Oncology</i> , 2017, 10, 229-240.	1.7	37
666	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 319-327.	1.0	11
667	High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase. <i>Oncology Reports</i> , 2017, 38, 2787-2795.	1.2	9
668	Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216.		0
669	EGFR-targeted therapies in the post-genomic era. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 463-473.	2.7	182
670	Progress in the treatment of advanced gastric cancer. <i>Tumor Biology</i> , 2017, 39, 101042831771462.	0.8	647
671	Application of Digital PCR in Detecting Human Diseases Associated Gene Mutation. <i>Cellular Physiology and Biochemistry</i> , 2017, 43, 1718-1730.	1.1	40
672	Capilliposide from <i>Lysimachia capillipes</i> inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 100-109.	2.8	14
673	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 223-236.	0.9	16
674	Care of cancer patients with liver and bone metastases – the place of pharmaceutical care in a balanced plan, focused on the patient’s needs and goals. <i>Archives of Medical Science</i> , 2017, 6, 1483-1492.	0.4	5
675	Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 59552-59562.	0.8	10
676	A putative G-quadruplex structure in the proximal promoter of VEGFR-2 has implications for drug design to inhibit tumor angiogenesis. <i>Journal of Biological Chemistry</i> , 2018, 293, 8947-8955.	1.6	21
677	Heterogeneity in Lung Cancer. <i>Pathobiology</i> , 2018, 85, 96-107.	1.9	202
678	Stat5 phosphorylation is responsible for the excessive potency of HB-EGF. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 5297-5307.	1.2	6

#	ARTICLE	IF	CITATIONS
679	First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 443-453.	1.1	10
680	A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 527-535.	1.4	16
681	High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma. <i>Medicine (United States)</i> , 2018, 97, e0203.	0.4	20
682	Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient. <i>Gene</i> , 2018, 644, 87-92.	1.0	11
683	Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU. <i>Molecular Cancer Research</i> , 2018, 16, 212-221.	1.5	21
684	The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review. <i>Oncology Reviews</i> , 2018, 12, 346.	0.8	6
685	Integrating the DNA damage and protein stress responses during cancer development and treatment. <i>Journal of Pathology</i> , 2018, 246, 12-40.	2.1	79
686	Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways. <i>BioMed Research International</i> , 2018, 2018, 1-15.	0.9	45
687	Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3697-3703.	1.0	5
688	The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2637-2646.	1.0	8
689	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. <i>Clinical Drug Investigation</i> , 2018, 38, 639-648.	1.1	20
690	Pharmacodynamics of current and emerging treatments for cervical cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 671-682.	1.5	18
691	&lt;p&gt;Monoclonal antibody AC10364 inhibits cell proliferation in 5-fluorouracil resistant hepatocellular carcinoma via apoptotic pathways&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5053-5067.	1.0	6
692	Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2019, 20, 49.	1.3	6
693	Enhancement of the Marginal Area in Colorectal Cancer Liver Metastasis on Computed Tomography Correlates With Microvessel Density and Clinicopathological Factors. <i>Anticancer Research</i> , 2019, 39, 1301-1308.	0.5	2
694	The emerging roles of macrophages in cancer metastasis and response to chemotherapy. <i>Journal of Leukocyte Biology</i> , 2019, 106, 259-274.	1.5	80
695	Severe toxicity in adult patients with lung cancer under treatment with pemetrexed: a prospective cohort study. <i>Journal of Chemotherapy</i> , 2019, 31, 95-104.	0.7	5
696	Association of epidermal growth factor receptor (EGFR) gene polymorphisms with endometriosis. <i>Medicine (United States)</i> , 2019, 98, e15137.	0.4	3

#	ARTICLE	IF	CITATIONS
697	Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 943-958.	3.6	48
698	Slit/Robo Signaling Pathway in Cancer; a New Stand Point for Cancer Treatment. <i>Pathology and Oncology Research</i> , 2019, 25, 1285-1293.	0.9	16
699	Efficacy and Safety of Bisphosphonate Therapy in McCune-Albright Syndrome-Related Polyostotic Fibrous Dysplasia: A Single-Center Experience. <i>Endocrine Practice</i> , 2019, 25, 23-30.	1.1	23
700	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
701	FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1857-1868.	3.2	13
702	Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia. <i>Frontiers in Pediatrics</i> , 2020, 8, 582316.	0.9	3
703	Effects of vitamin B12 on methotrexate hepatotoxicity: evaluation of receptor-interacting protein (RIP) kinase. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 2473-2480.	1.4	12
704	New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. , 2020, 214, 107611.		50
705	EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2020, 2020, 1-14.	0.6	42
706	A stability-indicating LC-MS/MS method optimization for Pemetrexed through design of experiments: Identification and characterization of major oxidative degradation product. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 183, 113150.	1.4	9
707	Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	0
708	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. <i>Molecular Imaging and Biology</i> , 2021, 23, 70-83.	1.3	1
709	The Role of Introns for the Development of Inflammation-Mediated Cancer Cell. , 0, , .		0
710	Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha. <i>Frontiers in Oncology</i> , 2021, 11, 668798.	1.3	5
711	Ká¼T QUá»c Äá»«EU TRá»Š UNG THÆ PHá»”I KHÄ”NG Tá¼ BÄEO NHá»Ž GIAI ÄOá»N IIIB-IV Bá»NG PHÄC Äá»’ PEMETREXED ä»“ CİSIF Nam, 2021, 501, .	0.0	1
712	Folate Receptor Targeted Thymidylate Synthase Inhibitors. , 2011, , 93-117.		3
713	Mechanisms of Immune Dysfunction in Renal Cell Carcinoma. <i>Cancer Treatment and Research</i> , 2003, 116, 29-51.	0.2	16
714	Preclinical Models for Combination Therapy. , 2004, , 213-242.		2

#	ARTICLE	IF	CITATIONS
715	Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent. <i>Clinical Cancer Research</i> , 2004, 10, 4276s-4280s.	3.2	147
716	Expression of RFC/SLC19A1 is Associated with Tumor Type in Bladder Cancer Patients. <i>PLoS ONE</i> , 2011, 6, e21820.	1.1	13
717	Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome. <i>PLoS ONE</i> , 2012, 7, e30996.	1.1	32
718	First In-Mouse Development and Application of a Surgically Relevant Xenograft Model of Ovarian Carcinoma. <i>PLoS ONE</i> , 2014, 9, e89527.	1.1	20
719	Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. <i>PLoS ONE</i> , 2020, 15, e0228909.	1.1	66
720	Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review. <i>World Journal of Oncology</i> , 2014, 5, 232-236.	0.6	7
721	Cancer chemotherapy: targeting folic acid synthesis. <i>Cancer Management and Research</i> , 2010, 2, 293-301.	0.9	122
722	Effect of Folic Acid on Methotrexate Induction of Sulfotransferases in Rats. <i>Drug Metabolism Letters</i> , 2008, 2, 115-119.	0.5	5
723	Evaluation by different mechanisms of the protective effects of vitamin B12 on methotrexate nephrotoxicity. <i>Journal of Molecular Histology</i> , 2022, 53, 133-143.	1.0	3
724	Hematopoietic Progenitor Cell Transplantation for Breast Cancer. , 2004, , 99-132.		0
725	Drug–Nutrient Interactions Involving Folate. , 2009, , 513-536.		0
726	Experience of Combination Therapy Consisting of Carboplatin, Docetaxel, and Bevacizumab for Previously Treated Advanced Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2010, 50, 901-905.	0.0	1
727	Pharmacologie des cytotoxiques antitumoraux. , 2011, , 23-46.		0
728	Clinical Practice Guideline for Symptomatic Brain Radiation Necrosis. <i>Japanese Journal of Neurosurgery</i> , 2017, 26, 287-306.	0.0	3
730	Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. <i>Drug Safety</i> , 2021, 44, 1271-1281.	1.4	10
733	A closer look at the mode of binding of drug pemetrexed with CT-DNA. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, , 1-9.	2.0	0
734	Zoledronate promotes ECM degradation and apoptosis via Wnt/ $\beta$ 2-catenin. <i>Open Medicine (Poland)</i> , 2022, 17, 768-780.	0.6	0
735	Antifolate-based anticancer drugs. , 2022, , 35-67.		0



#	ARTICLE	IF	CITATIONS
736	Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non-Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial. <i>Clinical Cancer Research</i> , 2005, 11, 690-696.	3.2	97
737	Intravenous route for folate supplementation in a patient with celiac disease treated by pemetrexed-based chemotherapy for non-small-cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 750-754.	0.5	1
738	Polypharmacology in Clinical Applications Anticancer Polypharmacology. , 2022, , 73-132.		0
739	Translational Research in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
740	Lung Cancer Complicated by Relapsing Polychondritis. <i>Internal Medicine</i> , 2022, , .	0.3	0
741	A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. , 2023, 40, .		2